EGFR and colorectal carcinoma: Acknowledging that the results may be skewed by the limited number of CRC patients with BRAF mutation, controversial data have been published about the impact of anti-EGFR drugs on these patients, with some data suggesting a potential negative predictive role of BRAF mutations [48].